STAT3 and TP53 mutations associate with poor prognosis in anaplastic large cell lymphoma

Warning

This publication doesn't include Faculty of Medicine. It includes Central European Institute of Technology. Official publication website can be found on muni.cz.

Authors

LOBELLO Cosimo TICHÝ Boris BYSTRÝ Vojtěch RADOVÁ Lenka FILIP Daniel MRÁZ Marek MONTES-MOJARRO I.A. PROKOPH N. LAROSE H. LIANG H.C. SHARMA G.G. MOLOGNI L. BELADA D. KAMARADOVA K. FEND F. GAMBACORTI-PASSERINI C. MERKEL O. TURNER Suzanne Dawn JANÍKOVÁ Andrea POSPÍŠILOVÁ Šárka

Year of publication 2021
Type Article in Periodical
Magazine / Source Leukemia
MU Faculty or unit

Central European Institute of Technology

Citation
Web https://www.nature.com/articles/s41375-020-01093-1
Doi http://dx.doi.org/10.1038/s41375-020-01093-1
Keywords ALCL
Description Systemic anaplastic large cell lymphoma (sALCL) encompasses two distinct clinical entities of T-cell non-Hodgkin lymphoma: anaplastic lymphoma kinase-positive (ALK+) ALCL and ALK-negative (ALK-) ALCL. These entities are characterized by either the presence or absence of an ALK translocation. It has been reported that ALK+ ALCL has a better prognosis compared to ALK-, with a 5-year overall survival (OS) of 70–80% versus 40–60%, respectively, [1,2,3]. Furthermore, more than 30% of ALK+ ALCL patients relapse [4, 5]. Despite the distinction between the two sALCL subtypes, frontline treatment for adults is similar and is based on CHOP or CHOEP, instead pediatric ALCL patients are mainly treated following the ALCL99 protocol [6,7,8]. Whilst high-throughput genomic studies in sALCL have shown recurrent genetic alterations, their association with outcome has not been fully investigated [9,10,11,12,13]. In this study, the mutational landscape of sALCL patient tumors was investigated to discover potential biomarkers that may improve risk stratification and patient management.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.

More info